INmune Bio Inc Cash Flow Conversion Efficiency
INmune Bio Inc cash flow conversion efficiency. Based on the latest financial reports, INmune Bio Inc (INMB) has a cash flow conversion efficiency ratio of -0.323x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.58 Million) by net assets ($20.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of INmune Bio Inc (2015–2025)
Cash flow conversion efficiency of INmune Bio Inc from 2015 to 2025. This chart illustrates how INmune Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View INmune Bio Inc share price for real-time trading data and today's change.
INmune Bio Inc Cash Flow Conversion Ratio Explained
INmune Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
INmune Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of INmune Bio Inc ranked by their cash flow conversion efficiency. Also see INMB stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bluerock Homes Trust Inc.
NYSE MKT:BHM
|
0.021x |
|
Regal Holding Co Ltd
TW:4807
|
-0.239x |
|
EBR Systems Inc
AU:EBR
|
-0.605x |
|
City Of London Investment Trust
LSE:CTY
|
0.004x |
|
Smr Utama Tbk
JK:SMRU
|
0.656x |
|
Cineverse Corp.
NASDAQ:CNVS
|
-0.025x |
|
Advanced Braking Technology Ltd
AU:ABV
|
0.134x |
|
GigCapital7 Corp. Class A Ordinary Share
NASDAQ:GIG
|
-0.052x |
Annual Cash Flow Conversion Efficiency for INmune Bio Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of INmune Bio Inc from 2015 to 2025. Review INmune Bio Inc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $23.52 Million | $-22.58 Million | -0.960x | +7.64% |
| 2024-12-31 | $32.10 Million | $-33.36 Million | -1.039x | -230.89% |
| 2023-12-31 | $38.14 Million | $-11.98 Million | -0.314x | +16.78% |
| 2022-12-31 | $60.10 Million | $-22.69 Million | -0.377x | -6.23% |
| 2021-12-31 | $80.22 Million | $-28.50 Million | -0.355x | -53.96% |
| 2020-12-31 | $38.75 Million | $-8.94 Million | -0.231x | -1.19% |
| 2019-12-31 | $23.61 Million | $-5.38 Million | -0.228x | -83.20% |
| 2018-12-31 | $16.54 Million | $-2.06 Million | -0.124x | -195.83% |
| 2017-12-31 | $18.10 Million | $-761.83K | -0.042x | -101.98% |
| 2016-12-31 | $-149.20K | $-317.38K | 2.127x | +121.52% |
| 2015-12-31 | $-18.87K | $-18.12K | 0.960x | -- |
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of pati… Read more